Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin modulation of serotonin pathways in ASD
NCT05651126Completed
- Sponsor
- King's College London
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of psilocybin in Autism Spectrum Disorder (ASD) (3 arms), sponsored by King's College London. Primary endpoints: Brain activation and connectivity response to serotonergic stimulation, Brain electrophysiological activity task-free electroencephalography and 2 more. Started Dec 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05651126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651126.